Fibromyalgia related Press Releases
European CHMP Adopts Negative Opinion on Eli Lilly, Boehringer Ingelheim's Cymbalta for the Treatment of Fibromyalgia
European CHMP Adopts Negative Opinion on Eli Lilly, Boehringer Ingelheim's Cymbalta for the Treatment of Fibromyalgia INDIANAPOLIS, Oct. 24 /PRNewswire-FirstCall/ -- The Committee for Medicinal
... Read more...Forest Laboratories, Cypress Bioscience Fibromyalgia Drug Delayed at FDA
Forest Laboratories, Cypress Bioscience Fibromyalgia Drug Delayed at FDA NEW YORK and SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX - News) and Cypress Bioscience,... Read more...
JAZZ PHARMACEUTICALS, INC. ANNOUNCES FINAL PATIENT HAS COMPLETED PHASE III CLINICAL TRIAL OF SODIUM OXYBATE TO TREAT FIBROMYALGI
JAZZ PHARMACEUTICALS, INC. ANNOUNCES FINAL PATIENT HAS COMPLETED PHASE III CLINICAL TRIAL OF SODIUM OXYBATE TO TREAT FIBROMYALGIA PALO ALTO, Calif., Sept. 11 -- Jazz Pharmaceuticals, Inc. (Nasdaq:... Read more...
PRESS RELEASE: Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome
Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show NEW YORK, Nov. 8 -- Total daily dosages of milnacipran 100 mg and 200 mg... Read more...
PRESS RELEASE: Sosei Drug Misses Goal in Fibromyalgia Trial
Sosei Drug Misses Goal in Fibromyalgia Trial TOKYO, September 18 -- Sosei Group Corporation , the biopharmaceutical company, today announces that AD 337, an enantiomer of an approved, centrally... Read more...
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




